Nina Radosevic-Robin

List of Publications by Year
in descending order

50	1,990	304743	276875
papers	citations	22 h-index	41 g-index

55	55	55	4228
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology, 2018, 52, 16-25.	9.6	303
2	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	5.5	230
3	Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. Journal of Oncology, 2017, 2017, 1-15.	1.3	171
4	Ki67 assessment in breast cancer: an update. Pathology, 2017, 49, 166-171.	0.6	157
5	A stemness-related ZEB1â€“MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nature Medicine, 2017, 23, 568-578.	30.7	131
6	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. Science Signaling, 2014, 7, ra29.	3.6	123
7	Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clinical Cancer Research, 2017, 23, 2806-2816.	7.0	82
8	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer, 2020, 23, 73-81.	5.3	75
9	Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Critical Reviews in Oncology/Hematology, 2015, 95, 88-104.	4.4	72
10	BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells. PLoS ONE, 2014, 9, e102438.	2.5	54
11	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncology, The, 2021, 22, e18-e28.	10.7	49
12	Stratification and therapeutic potential of PML in metastatic breast cancer. Nature Communications, 2016, 7, 12595.	12.8	45
13	HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget, 2014, 5, 7138-7148.	1.8	43
14	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nature Reviews Clinical Oncology, 2016, 13, 487-503.	27.6	43
15	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced nonâ€“small cell lung cancer treated with immunotherapy. European Journal of Cancer, 2021, 145, 221-229.	2.8	42
16	Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer, 2018, 18, 129.	2.6	40
17	Quantification of HER family receptors in breast cancer. Breast Cancer Research, 2015, 17, 53.	5.0	39
18	SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Research and Treatment, 2015, 154, 351-357.	2.5	35

#	Article	IF	Citations
19	An auristatinâ€‐based antibodyâ€‐drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. International Journal of Cancer, 2019, 145, 1838-1851.	5.1	33
20	Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. Blood, 2015, 125, 2448-2449.	1.4	28
21	Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma. Medicine (United States), 2018, 97, e13676.	1.0	28
22	STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway. Oncogene, 2021, 40, 6627-6640.	5.9	26
23	Combination of m<scp>TOR</scp> and <scp>EGFR</scp> targeting in an orthotopic xenograft model of head and neck cancer. Laryngoscope, 2016, 126, E156-63.	2.0	24
24	Combination of phosphotidylinositolâ€‐3â€‐kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. Head and Neck, 2017, 39, 151-159.	2.0	19
25	Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients. Frontiers in Oncology, 2021, 11, 678315.	2.8	17
26	Tumor mutational burden in non-small cell lung cancerâ€”the pathologistâ€™s point of view. Translational Lung Cancer Research, 2018, 7, 716-721.	2.8	10
27	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. Breast, 2021, 59, 183-192.	2.2	10
28	Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review. Breast Cancer Research and Treatment, 2022, 193, 265-279.	2.5	10
29	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. Npj Breast Cancer, 2021, 7, 124.	5.2	7
30	[18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer. EJNMMI Research, 2020, 10, 2.	2.5	6
31	Sensitive and Specific Detection of Ewing Sarcoma Minimal Residual Disease in Ovarian and Testicular Tissues in an In Vitro Model. Cancers, 2019, 11, 1807.	3.7	4
32	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. MAbs, 2021, 13, 1914883.	5.2	4
33	PERCEPTION Trial protocol. Medicine (United States), 2020, 99, e23418.	1.0	4
34	WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells. Cancers, 2022, 14, 1487.	3.7	4
35	Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, e15537-e15537.	1.6	2
36	INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 653370.	2.8	2

#	Article	IF	Citations
37	XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal bÂbreast cancer. F1000Research, 2020, 9, 1219.	1.6	2
38	Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study. Clinical Breast Cancer, 2017, 17, 107-116.	2.4	1
39	Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC): The immune and IGFR pathways.. Journal of Clinical Oncology, 2013, 31, 1058-1058.	1.6	1
40	Abstract 1465: Analysis of tumor-infiltrating lymphocytes (TILs) reveals biologically different subgroups of breast ductal carcinoma in situ. , 2016, , .		1
41	Abstract 5803: Homoharringtonine, a natural protein synthesis inhibitor, inhibits growth of triple negative breast cancer in vitro and in vivo. Cancer Research, 2018, 78, 5803-5803.	0.9	1
42	Abstract 4669: Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC): the immune and IGFR pathways.. , 2013, , .		0
43	Pathologic complete response (pCR) to predict patientsâ€™ survival in luminal breast cancer.. Journal of Clinical Oncology, 2013, 31, e11615-e11615.	1.6	0
44	Cetuximab in combination with docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicentre neoadjuvant pilot phase II study.. Journal of Clinical Oncology, 2013, 31, 1057-1057.	1.6	0
45	Abstract NG01: Blockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triple negative breast cancer. , 2014, , .		0
46	Abstract 1819: Heterogeneity of triple-negative breast cancer response to neoadjuvant treatment: tumor EGFR, HER3 and MET expressions can provide clues for therapy tailoring. , 2014, , .		0
47	Abstract 550: Genomic instability and telomere characteristics as predictive biomarkers of therapeutic response in triple-negative breast cancer. , 2014, , .		0
48	Proliferation Markers in Breast Cancer. , 2016, , 81-98.		0
49	Abstract P1-08-24: Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients. Cancer Research, 2022, 82, P1-08-24-P1-08-24.	0.9	0
50	Neoadjuvant radiotherapy in triple-negative breast cancer: "the past should not steal the present or hide the future".. Reports of Practical Oncology and Radiotherapy, 2022, 27, 180-181.	0.6	0